Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on June 3, 2013. The report details the completion of the divestiture of its Canadian pharmaceutical distribution business, AmerisourceBergen Canada Corporation (ABCC), to Kohl & Frisch Limited. The Company retained its Canadian specialty business.
Key Financial Metrics
- Loss on Sale and Impairment: $161.7 million recorded in the quarter ended March 31, 2013.
- Reporting Classification: Results of operations for ABCC and associated charges are reported in discontinued operations.
- Adjustments: The recorded loss is subject to post-closing purchase price adjustments.
- Other Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the current period.
Material Changes
The primary material change is the exit from the Canadian pharmaceutical distribution market via the sale of ABCC. This transaction resulted in a significant one-time charge of $161.7 million recognized in the first quarter of 2013, impacting the Company's financial results for that period.
Outlook, Risks, and Contingencies
The Company expects to finalize post-closing purchase price adjustments with Kohl & Frisch Limited during the quarter ending September 30, 2013. These adjustments may alter the final recorded loss on the transaction. No other specific guidance or risk factors were detailed in this specific filing beyond the transaction completion.
Investor Verification Checklist
- Verify the final purchase price adjustments expected to be finalized in the quarter ending September 30, 2013.
- Confirm the exact impact of the $161.7 million charge on the Q1 2013 earnings per share and net income.
- Review the scope of the retained Canadian specialty business to understand remaining exposure in the region.
- Check subsequent filings for the finalized loss amount after purchase price adjustments are completed.